Eagle Earnings Reports

Eagle Pharmaceuticals reported a strong second quarter with total revenue of $64.6 million and net income of $5.2 million, or $0.39 per basic and diluted share. The company's marketed drugs across oncology and its hospital business performed well, leading to raised full-year guidance and resumption of the share repurchase program.

Eagle Pharmaceuticals reported a strong Q4 2022, with a significant increase in total revenue to $60.7 million compared to $42.3 million in Q4 2021. Net income for the quarter was $8.2 million, a substantial improvement from the net loss of $(6.2) million in the same quarter of the previous year. The company's success was driven by growth in product sales, including PEMFEXY, and effective management of its bendamustine franchise.

Eagle Pharmaceuticals reported a strong third quarter with total revenue increasing to $65.9 million compared to $39.9 million in Q3 2021. The company reported a net loss of $(0.27) per share, but adjusted non-GAAP net income was $1.13 per basic and $1.12 per diluted share. The company is seeing record earning this year and expects another strong year in 2023.

Eagle Pharmaceuticals reported a strong second quarter in 2022, with total revenue of $74.1 million compared to $48.1 million in Q2 2021. The company's adjusted non-GAAP earnings per basic share for the first half of 2022 more than doubled compared to the full year 2021, marking the best earnings performance in the company's history.

Eagle Pharmaceuticals reported Q4 2021 financial results with a net loss of $(0.48) per share and adjusted non-GAAP net income of $0.85 per diluted share. The company launched two new products, vasopressin and PEMFEXY, and anticipates a strong Q1 2022.

Eagle Pharmaceuticals reported a decrease in revenue to $39.9 million compared to $49.9 million in the same quarter last year. The company experienced a net loss of $5.6 million, or $0.43 per share, compared to a net income of $7.1 million, or $0.52 per share, in the third quarter of 2020. However, adjusted non-GAAP net income was $7.5 million, or $0.57 per share.

Eagle Pharmaceuticals reported a strong Q2 2021 with total revenue of $48.1 million, driven by higher product sales of BELRAPZO® and RYANODEX®. The company also announced a licensing agreement for Landiolol and anticipates the commercial launch of vasopressin by year-end.

Eagle Pharmaceuticals reported Q1 2021 results with total revenue of $41.2 million compared to $46.0 million in Q1 2020. The company had a net loss of $0.4 million, or $0.03 per share, and an adjusted non-GAAP net income of $3.2 million, or $0.24 per share.

Eagle Pharmaceuticals reported a strong earnings year with a 36% year-over-year growth, despite challenges from the COVID-19 pandemic. The company's balance sheet remains healthy, supporting development programs and future growth. Key pipeline products like vasopressin, fulvestrant, and Ryanodex for nerve agent exposure show significant opportunities.

Eagle Pharmaceuticals reported a strong third quarter with total revenue of $49.9 million, driven by BELRAPZO and RYANODEX product sales growth and royalty revenue. Net income was $7.1 million, or $0.52 per basic share. The company is advancing multiple near-term product opportunities and welcomes new pharmaceutical executives to the team.

Eagle Pharmaceuticals reported Q2 2020 revenue of $41.9 million, a net loss of $0.3 million, and an adjusted non-GAAP net income of $8.0 million. The company is advancing its pipeline of oncology and critical care products and anticipates the launch of vasopressin.

Eagle Pharmaceuticals reported Q4 2019 revenue of $48.3 million compared to $56.1 million for the three months ended December 31, 2018. Net income for the fourth quarter of 2019 was $1.0 million, or $0.07 per basic and diluted share, compared to net income of $12.6 million, or $0.88 per basic and $0.86 per diluted share, in the fourth quarter of 2018. Adjusted non-GAAP net income for the fourth quarter of 2019 was $6.7 million, or $0.49 per basic and $0.48 per diluted share, compared to adjusted non-GAAP net income of $17.7 million or $1.23 per basic and $1.20 per diluted share in the fourth quarter of 2018.